Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat-Reference-Cited by-同舟云学术

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

Published:2011-04 Issue:4 Volume:57 Page:495-504
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:Journal of Cardiovascular Pharmacology

Author:

Hegde Laxminarayan G,Yu Cecile,Renner Travis,Thibodeaux Harold,Armstrong Scott R,Park Timothy,Cheruvu Madhavi,Olsufka Rachael,Sandvik Erik R,Lane Cassie E,Budman Joe,Hill Craig M,Klein Uwe,Hegde Sharath S

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference46 articles.

1. Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004

2. State of the heart in the USA

3. Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

4. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inibidores da Neprilisina: Histórico, Farmacologia, Evidência Farmacológico-clínica e Prática Clínica, do Risco de Angioedema ao Pilar Terapêutico na Insuficiência Cardíaca;ABC Heart Failure & Cardiomyopathy;2024-07-11

2. Efficacy and Safety of Sacubitril/Valsartan in Adverse Cardiovascular Event Reduction and Hypertension Control Among Asians: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Philippine Journal of Cardiology;2024-06-15

3. Neprilysin Inhibitors: History, Pharmacology, Pharmacological-Clinical Evidence, and Clinical Practice, from the Risk of Angioedema to a Pillar of Therapy in Heart Failure;ABC Heart Fail Cardiomyop;2024

4. We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”;Statistics in Biopharmaceutical Research;2023-04-03

5. Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials;Frontiers in Cardiovascular Medicine;2022-09-08